Emerging Strategies in the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis

Complimentary

Released on 5/2/22
Expires on 5/2/23

Categories: , , , , , , , , , ,
Illustration of nerve cells and spinal cord anatomy.

Start Activity

Program Description

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of the upper and lower motor neurons. Patients with ALS typically experience progressive muscle weakness and atrophy, fasciculations, and speech and swallowing difficulties. The clinical spectrum of ALS is both heterogeneous and complex; the level of involvement of upper and lower motor neurons varies, as does the site of onset and the rate of disease progression. The four commonly identified phenotypes of ALS are (1) progressive muscular atrophy, with only lower motor neuron involvement; (2) limb-onset ALS, with both upper motor neuron and lower motor neuron involvement (also known as flail leg or flail arm); (3) bulbar-onset ALS, with swallowing and speech difficulties presenting early in the disease course and limb features occurring later; and (4) primary lateral sclerosis, with pure upper motor neuron involvement. There is no cure for ALS. Nonpharmacological and pharmacological therapies are available to help manage symptoms, alongside approved disease-modifying treatments.

Intended Audience

This webcast is designed to meet the educational needs of neurologists, internists, and other health care professionals (eg, primary care physicians, nurse practitioners, and physician assistants) involved in treating patients with ALS.

Commercial Supporter

This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America Inc.

No in-kind commercial support was received for this educational activity.

Educational Objectives

Upon completion of the educational activity, participants should be able to:

  • Analyze the underlying pathophysiology of ALS and the barriers to accurate and early diagnosis
  • Utilize interdisciplinary strategies to manage the systemic burden for patients with ALS
  • Discuss the efficacy and safety of disease-targeting and supportive therapies for patients with ALS
  • Identify challenges and opportunities in using shared decision-making and supporting patient adherence

Accredited Providers

Jointly provided by Amedco, a CME/CE company, and MedNet

  

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco and MedNet. Amedco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation

Designation Statement

Amedco designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) Credit Designation

Designation Statement

Amedco designates this enduring material activity for a maximum of 1.25 ANCC contact hours.

Additional Credit Information

Note to Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.25 hours.

Note to Physician Assistants
AAPA accepts AMA PRA Category 1 Credit(s)TM for the PRA from organizations accredited by ACCME. Maximum of 1.25 hours.

Planners’ and Managers’ Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Kamatham A. Naidu, PhD (MedNet) has no relevant financial relationships to disclose.
Brian Waggoner (MedNet) has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Conflicts of Interest Policy

It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (ie, course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Disclosure of Unlabeled Use

It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Non-Endorsement of Products

Amedco does not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Disclosure of Conflict of Interest

The following disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5).

All individuals in a position to control the content of CE are listed below.

Faculty

Senda Ajroud-Driss, MD 
Associate Professor of Neurology
Director of the Lois Insolia ALS Clinic
Les Turner ALS Center
Northwestern University
Chicago, IL

Senda Ajroud-Driss, MD, discloses that she is on the advisory board of Biogen, Amylyx and Orphazyme; and received research funding from Biogen and Amylyx.

Instructions

There are no fees for participating and receiving CME/CE credit for this webcast. During the period from April 4, 2022, through April 4, 2023, participants must read all the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 75% or better on the post-assessment is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

If you have any questions relating to the accreditation of this activity, please contact the CME/CE Provider at certificate@amedcoemail.com.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

Amedco observes privacy and confidentiality of CME/CE information and personal information of CME/CE participants. Third parties receive only aggregated data about CME/CE activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

Webcast

Time to Complete: 1.25 hours

Released: May 2, 2022

Expires: May 2, 2023

Maximum Credits:
1.25 / AMA PRA Category 1 CreditsTM
1.25 / ANCC Contact Hours

Related products